Notice Regarding Application for Marketing Authorization Holder License for Regenerative Medical Products

—Towards obtaining the License for Marketing Authorization Holder required for the domestic marketing of the stem cell product "Stemchymal®"—

June 18, 2026

REPROCELL Inc. (the "Company") hereby announces that as of June 18, 2026, the Company has submitted an application for a "License for Marketing Authorization Holder of Regenerative Medical Products" to Kanagawa Prefecture.
This application is intended to obtain the business license legally required to establish a framework enabling the Company to independently release and distribute its regenerative medical product, "Stemchymal®"—indicated for spinocerebellar ataxia, for which the Company holds an exclusive commercialization license agreement in Japan —promptly upon receiving regulatory marketing approval.
The Company is currently proceeding with its preparations for the marketing approval application in order to deliver this new treatment to patients fighting the disease as early as possible.

The impact of this matter on the Company's consolidated financial performance is currently expected to be minor; however, should any matters requiring disclosure arise in the future, the Company will promptly disclose them.

Glossary

Marketing Authorization Holder (MAH): This refers to the statutory entity that releases and distributes pharmaceuticals and regenerative medical products to the domestic market, bearing the ultimate legal responsibility for their quality and safety. Obtaining a License for Marketing Authorization Holder from the regulatory authority is legally required to conduct this business.